Abstract
With the recent cloning and recombinant expression of novel islet autoantigens, it is possible to investigate whether the quantitative expression of autoantibodies to these molecules is correlated with the semiquantitative titration of islet cell antibodies (ICA). To estimate the regional difference in the degree of association between these autoantibodies, autoantibodies reacting with ICA512/IA-2 (ICA512) and GAD65 in addition to ICA were analyzed in 131 Korean children with type 1 diabetes. Among the 131 type 1 diabetes patients, 36% was ICA512-positive, 56% was anti-GAD65-positive, and 43% was ICA-positive. However, in a subset of these with recent onset (<1 year), the prevalences of ICA512, anti-GAD65, and ICA were 75%, 75%, and 87.5%, respectively. ICA512 as well as anti-GAD65 were significantly associated with the presence of ICA. Among type 1 diabetes patients, 69% had one or more and 43% had two or more of these autoantibodies. Autoantibodies to ICA512 and anti-GAD65 were observed in 40 and in 41 of 56 ICA-positive subjects, respectively. Furthermore, ICA512 or anti-GAD65 were positive in 97% (34 of 35) and 100% (22 of 22) of patients with ICA levels > or =20 JDF-u and > or =40 JDF-u, respectively. The titer of ICA correlated with those of ICA512 (r=0.41, p<0.001) and anti-GAD65 (r=0.49, p<0.001). Both the prevalences and the titers of ICA512 or anti-GAD65 were strongly correlated with those of ICA even in Korean type 1 diabetes patients. ICA512 and anti-GAD65 in combination may be considered to be an alternative to ICA.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.